Ohio State Navbar

Sign In

RSS Feed Regenerative Medicine News


ImmunoCellular Therapeutics' Investigational New Drug (IND) Application for ICT-140 Allowed by the FDA 

 

January 29, 2013 - (ImmunoCellular) - "ImmunoCellular Therapeutics, Ltd. announced that the US Food and Drug Administration (FDA) has allowed the investigational new drug (IND) application for ICT-140, paving the way for conducting a clinical trial. ICT-140 is a dendritic cell vaccine targeting seven antigens that are over-expressed in ovarian cancer, as well as cancer stem cells." Read Full Press Release

 

Posted on 4-Feb-13 by Gallerno, Jacob
Tags: Science and Industry News
 
Trackback Url  |  Link to this post | Bookmark this post with: